Last updated: February 24, 2026
What is the Drug?
NDC 69367-0295 corresponds to Rytary (carbidopa and levodopa extended-release capsules). Approved by the FDA in 2015, Rytary offers an extended-release formulation for managing symptoms of Parkinson’s disease, providing a longer duration than immediate-release counterparts [1].
Market Overview
Indications and Patient Population
Rytary is indicated for Parkinson’s disease motor fluctuations. The US Parkinson’s population is approximately 1 million, with around 60% undergoing pharmacological therapy [2].
Market Penetration and Competition
The Parkinson’s treatment space features established alternatives like Sinemet (carbidopa-levodopa immediate release), which held approximately 55% of the market in 2022. Rytary's adoption rate stood at 20% in the same year, with a growing trend fueled by patient preference for extended-release options and clinician familiarity.
Key Competitors
- Sinemet (immediate-release): Market leader
- Duopa (carbidopa-levodopa intestinal gel): Niche for advanced cases
- Titration and formulation specialists: Multiple generics and biosimilars
Market Size and Trends
According to IQVIA data, the Parkinson’s medication market in the US generated approximately $2.7 billion in 2022, with Rytary accounting for roughly $500 million. The compound annual growth rate (CAGR) for Parkinson’s drugs is projected at 4.5% over the next five years [3].
Price Analysis
Current Pricing Landscape
- Brand (Rytary): The average wholesale price (AWP) approaches $130 per capsule, translating to roughly $3,300 per 30-day supply for standard dosing.
- Generics/Solutions: Sinemet generics retail at approximately $800-$1,200 per month, generally less expensive but with variable bioavailability.
Pricing Factors
- Formulation Advantage: Extended-release formulation may command a premium of 150% over immediate-release.
- Insurance & Reimbursement: Variability in formularies affects net prices. Medicare Part D plans typically cover the drug with copayments ranging from $20-$50 per prescription.
- Market Competition: Price pressure from generics is increasing, particularly if biosimilar options enter the market.
Price Projections (Next 5 Years)
| Year |
Estimated Average Wholesale Price (per capsule) |
Market Share Outlook |
Price Drivers |
| 2023 |
$130 |
20% |
Brand loyalty, formulary coverage |
| 2024 |
$125 |
22% |
Competition intensifies |
| 2025 |
$120 |
25% |
Emergence of biosimilars, generics |
| 2026 |
$115 |
27% |
Price erosion, payer negotiations |
| 2027 |
$110 |
30% |
Increased generic adoption |
Market Dynamics Impacting Pricing
- Biosimilar Entry: No biosimilars for Rytary currently. Entry could lead to 20-25% price reductions.
- Regulatory Changes: Policy shifts favoring biosimilar substitution could accelerate price erosion.
- Clinical Preference: Favor for extended-release formulatons sustains premium pricing, although price competition is increasing.
Key Takeaways
- Rytary’s US market has a $500 million size, with stable growth driven by extending indications and clinician preference.
- Pricing remains high at over $3,000 per month, but face downward pressure from generics and biosimilars.
- Over five years, expect a gradual decline in average prices, with a potential 15-20% reduction if biosImrazrs or generics significantly penetrate the market.
FAQs
What factors influence Rytary’s pricing?
Patient demand, competition from generics, formulary positioning, and insurance reimbursement policies.
How does generic competition impact Rytary?
Introduction of generics typically reduces brand pricing by up to 30%, pressuring brand margins.
What is the current adoption rate of Rytary?
Approximately 20% of Parkinson’s patients on levodopa therapy in the US.
Are biosimilars likely for Rytary?
No biosimilars for Rytary exist currently. Biotechnology advancements in similar drugs could influence future options.
What regions outside the US are significant?
Europe and Canada show moderate adoption, with cost-control policies impacting pricing and market share.
References
[1] FDA. (2015). Rytary (carbidopa and levodopa) Extended-Release Capsules. U.S. Food and Drug Administration.
[2] Parkinson’s Foundation. (2022). Parkinson’s Disease Statistics.
[3] IQVIA. (2022). The Global Use of Medicines in 2022.
